These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 33148404)

  • 1. Formulation composition, manufacturing process, and characterization of poly(lactide-co-glycolide) microparticles.
    Park K; Otte A; Sharifi F; Garner J; Skidmore S; Park H; Jhon YK; Qin B; Wang Y
    J Control Release; 2021 Jan; 329():1150-1161. PubMed ID: 33148404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surface analysis of sequential semi-solvent vapor impact (SAVI) for studying microstructural arrangements of poly(lactide-co-glycolide) microparticles.
    Garner J; Skidmore S; Hadar J; Park H; Park K; Qin B; Wang Y
    J Control Release; 2022 Oct; 350():600-612. PubMed ID: 36057396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Injectable, long-acting PLGA formulations: Analyzing PLGA and understanding microparticle formation.
    Park K; Skidmore S; Hadar J; Garner J; Park H; Otte A; Soh BK; Yoon G; Yu D; Yun Y; Lee BK; Jiang X; Wang Y
    J Control Release; 2019 Jun; 304():125-134. PubMed ID: 31071374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beyond Q1/Q2: The Impact of Manufacturing Conditions and Test Methods on Drug Release From PLGA-Based Microparticle Depot Formulations.
    Garner J; Skidmore S; Park H; Park K; Choi S; Wang Y
    J Pharm Sci; 2018 Jan; 107(1):353-361. PubMed ID: 29107048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential Roles of the Glass Transition Temperature of PLGA Microparticles in Drug Release Kinetics.
    Park K; Otte A; Sharifi F; Garner J; Skidmore S; Park H; Jhon YK; Qin B; Wang Y
    Mol Pharm; 2021 Jan; 18(1):18-32. PubMed ID: 33331774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered PLGA microspheres for extended-release of naltrexone:
    Ghareh Sheikhlou M; Shabani Ravari N; Behrouzi M; Goodarzi N; Saghafian Larijani R; Varshochian R; Dinarvand R; Rouini MR
    Pharm Dev Technol; 2023 Feb; 28(2):190-199. PubMed ID: 36688610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complex sameness: Separation of mixed poly(lactide-co-glycolide)s based on the lactide:glycolide ratio.
    Skidmore S; Hadar J; Garner J; Park H; Park K; Wang Y; Jiang XJ
    J Control Release; 2019 Apr; 300():174-184. PubMed ID: 30853529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Manufacturing Variables and Raw Materials on the Composition-Equivalent PLGA Microspheres for 1-Month Controlled Release of Leuprolide.
    Zhou J; Walker J; Ackermann R; Olsen K; Hong JKY; Wang Y; Schwendeman SP
    Mol Pharm; 2020 May; 17(5):1502-1515. PubMed ID: 32074448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial Formation of the Skin Layer of PLGA Microparticles.
    Sharifi F; Otte A; Park K
    Adv Healthc Mater; 2022 Apr; 11(7):e2101427. PubMed ID: 34601826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scanning Analysis of Sequential Semisolvent Vapor Impact To Study Naltrexone Release from Poly(lactide-co-glycolide) Microparticles.
    Garner J; Skidmore S; Hadar J; Park H; Park K; Otte A; Jhon YK; Xu X; Qin B; Wang Y
    Mol Pharm; 2022 Nov; 19(11):4286-4298. PubMed ID: 36166409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of PLGA Variability in Controlled Drug Release from Dexamethasone Intravitreal Implants.
    Costello MA; Liu J; Kuehster L; Wang Y; Qin B; Xu X; Li Q; Smith WC; Lynd NA; Zhang F
    Mol Pharm; 2023 Dec; 20(12):6330-6344. PubMed ID: 37955890
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reverse engineering of Perseris and development of compositionally equivalent formulations.
    Wang X; Bao Q; Wang R; Wan B; Wang Y; Qin B; Burgess DJ
    Int J Pharm; 2023 May; 639():122948. PubMed ID: 37044228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of poly(lactide-co-glycolide) microparticles for sustained delivery of meloxicam.
    Pei Y; Wang J; Khaliq NU; Meng F; Oucherif KA; Xue J; Horava SD; Cox AL; Richard CA; Swinney MR; Park K; Yeo Y
    J Control Release; 2023 Jan; 353():823-831. PubMed ID: 36521690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interfacial tension effects on the properties of PLGA microparticles.
    Otte A; Sharifi F; Park K
    Colloids Surf B Biointerfaces; 2020 Dec; 196():111300. PubMed ID: 32919245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and characterization of composition-equivalent formulations to the Sandostatin LAR® by the solvent evaporation method.
    Beig A; Feng L; Walker J; Ackermann R; Hong JKY; Li T; Wang Y; Schwendeman SP
    Drug Deliv Transl Res; 2022 Mar; 12(3):695-707. PubMed ID: 34215997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of formulation parameters on 2-methoxyestradiol release from injectable cylindrical poly(DL-lactide-co-glycolide) implants.
    Desai KG; Mallery SR; Schwendeman SP
    Eur J Pharm Biopharm; 2008 Sep; 70(1):187-98. PubMed ID: 18472254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transitioning from a lab-scale PLGA microparticle formulation to pilot-scale manufacturing.
    Otte A; Park K
    J Control Release; 2022 Aug; 348():841-848. PubMed ID: 35752252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Manufacturing of Dexamethasone-Poly(d,l-Lactide-co-Glycolide) Implants Using Hot-Melt Extrusion: Within- and Between-Batch Product Performance Comparisons.
    Kelley RA; Ghaffari A; Wang Y; Choi S; Taylor JR; Hartman RR; Kompella UB
    J Ocul Pharmacol Ther; 2020 Jun; 36(5):290-297. PubMed ID: 32330403
    [No Abstract]   [Full Text] [Related]  

  • 19. Continuous in-line homogenization process for scale-up production of naltrexone-loaded PLGA microparticles.
    Sharifi F; Otte A; Yoon G; Park K
    J Control Release; 2020 Sep; 325():347-358. PubMed ID: 32645336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Injectable long-acting ivacaftor-loaded poly (lactide-co-glycolide) microparticle formulations for the treatment of cystic fibrosis: In vitro characterization and in vivo pharmacokinetics in mice.
    Nakhla DS; Mekkawy AI; Naguib YW; Silva AD; Gao D; Ah Kim J; Alhaj-Suliman SO; Acri TM; Kumar Patel K; Ernst S; Stoltz DA; Welsh MJ; Salem AK
    Int J Pharm; 2024 Jan; 650():123693. PubMed ID: 38081555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.